Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00699790 | Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance | PHASE2 | COMPLETED | 58 | — | — | Feb 1, 2009 | Dec 1, 2009 | Oct 12, 2015 | 12 | Russia |
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| A2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CCR2 Antagonist | DRUG | Tablets, Oral, 50 mg, once daily, 12 weeks |
| Placebo | DRUG | Tablets, Oral, 0mg, once daily, 12 weeks |
Inclusion Criteria: * Drug-naive Type 2 diabetics with a screening HbA1c of ≥ 7.5% and ≤ 10% * Screening FPG ≥ 140 mg/dL and ≤ 220 mg/dL * BMI ≤ 40 kg/m2 Exclusion Criteria: * Active tuberculosis * Symptoms of poorly controlled diabetes * History of diabetic ketoacidosis * Significant cardiovascu...